Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash & Current Investments (2020 - 2025)

Bioventus (BVS) has disclosed Cash & Current Investments for 6 consecutive years, with $51.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Current Investments rose 23.22% year-over-year to $51.2 million, compared with a TTM value of $51.2 million through Dec 2025, up 23.22%, and an annual FY2025 reading of $51.2 million, up 23.22% over the prior year.
  • Cash & Current Investments was $51.2 million for Q4 2025 at Bioventus, up from $42.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $138.1 million in Q3 2021 and bottomed at $23000.0 in Q4 2022.
  • Average Cash & Current Investments over 5 years is $48.1 million, with a median of $37.0 million recorded in 2023.
  • The sharpest move saw Cash & Current Investments crashed 99.98% in 2022, then skyrocketed 116539.13% in 2023.
  • Year by year, Cash & Current Investments stood at $49.2 million in 2021, then plummeted by 38.62% to $30.2 million in 2022, then rose by 22.36% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
  • Business Quant data shows Cash & Current Investments for BVS at $51.2 million in Q4 2025, $42.2 million in Q3 2025, and $32.9 million in Q2 2025.